^
    5d
    Clinical strategies for lymphoma management: Recommendations from the Bridging the Gaps in Leukemia, Lymphoma, and Multiple Myeloma Consensus Conference 2025. (PubMed, Cancer)
    Key recommendations include the screening for high-risk features in MCL, use of the BOVen regimen (zanubrutinib, obinutuzumab, and venetoclax) for TP53-aberrant cases, and integration of chimeric antigen receptor T-cell therapy for patients with mantle cell lymphoma that is refractory to covalent Bruton tyrosine kinase inhibitors. For DLBCL, this article highlights the challenges in treatment sequencing and the role of circulating tumor DNA and minimal residual disease testing in monitoring disease progression. Overall, the conference describes the importance of ongoing research to refine management strategies and improve patient outcomes in lymphoma care, addressing the gaps in clinical practice where high-level evidence is lacking.
    Journal
    |
    TP53 (Tumor protein P53)
    |
    Venclexta (venetoclax) • Gazyva (obinutuzumab) • Brukinsa (zanubrutinib)
    6d
    Phase II Palbociclib +Ibrutinib in Mantle Cell Lymphoma (clinicaltrials.gov)
    P2, N=39, Active, not recruiting, Alliance Foundation Trials, LLC. | Trial completion date: Mar 2026 --> Aug 2026 | Trial primary completion date: Mar 2026 --> Nov 2025
    Trial completion date • Trial primary completion date
    |
    CCND1 (Cyclin D1) • CD4 (CD4 Molecule) • CD5 (CD5 Molecule)
    |
    Chr t(11;14)
    |
    Ibrance (palbociclib) • Imbruvica (ibrutinib)
    6d
    Long-term Follow-up Study for Patients Treated With CLBR001 CAR-T (clinicaltrials.gov)
    P1, N=16, Completed, Calibr, a division of Scripps Research | N=36 --> 16 | Trial completion date: Aug 2036 --> Oct 2025 | Trial primary completion date: Aug 2036 --> Oct 2025 | Enrolling by invitation --> Completed
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date
    |
    CLBR001/SWI019
    9d
    Bruton protein-tyrosine kinase (BTK) FDA-approved small molecule inhibitors used for the management of neoplastic and inflammatory disorders. (PubMed, Pharmacol Res)
    Aberrant B cell receptor signaling occurs in several B cell neoplasms including follicular lymphoma (treated with zanubrutinib, a BTK inhibitor), mantle cell lymphoma (acalabrutinib, pirtobrutinib, zanubrutinib), marginal zone lymphoma (zanubrutinib), chronic lymphocytic leukemia and small lymphocytic lymphoma (ibrutinib, acalabrutinib, zanubrutinib, pirtobrutinib), and Waldenström macroglobulinemia (ibrutinib, zanubrutinib)...Pirtobrutinib fails to form a covalent bond and is a reversible BTK inhibitor. The FDA-approvals of rilzabrutinib and remibrutinib (2025) represent the first nononcologic authorizations for BTK antagonists.
    FDA event • Review • Journal
    |
    BTK (Bruton Tyrosine Kinase) • PLCG2 (Phospholipase C Gamma 2) • LYN (LYN Proto-Oncogene Src Family Tyrosine Kinase) • SYK (Spleen tyrosine kinase)
    |
    Imbruvica (ibrutinib) • imatinib • cyclophosphamide • Brukinsa (zanubrutinib) • Calquence (acalabrutinib) • vincristine • prednisone • Jaypirca (pirtobrutinib) • Rhapsido (remibrutinib)
    14d
    Memory Enriched T Cells Following Stem Cell Transplant in Treating Patients With Recurrent B-Cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1, N=51, Active, not recruiting, City of Hope Medical Center | Trial completion date: Mar 2026 --> Mar 2027 | Trial primary completion date: Mar 2026 --> Mar 2027
    Trial completion date • Trial primary completion date
    |
    CD19 CAR T cells
    15d
    A Randomized, Open-label, Multi-center, Phase III Study of Orelabrutinib in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) vs. R-CHOP Alone in Patients With Treatment-naїve Mantle Cell Lymphoma (clinicaltrials.gov)
    P3, N=3, Completed, Beijing InnoCare Pharma Tech Co., Ltd. | Recruiting --> Completed | N=356 --> 3 | Trial completion date: Dec 2027 --> Jun 2025 | Trial primary completion date: Dec 2024 --> Jun 2025
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date
    |
    CD20 (Membrane Spanning 4-Domains A1) • CCND1 (Cyclin D1)
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • Inokai (orelabrutinib)
    15d
    Continuous Temperature Monitoring (CTM) for Cytokine Release Syndrome (CRS), an Immune-Related Adverse Event (clinicaltrials.gov)
    P=N/A, N=136, Not yet recruiting, National Cancer Institute (NCI)
    New trial • Adverse events
    17d
    FIL_COLUMN: Consolidation With Loncastuximab Tesirine After a Short Course of Immunochemotherapy in BTKi-treated (or Intolerant) Relapsed/Refractory Mantle Cell Lymphoma Patients. (clinicaltrials.gov)
    P2, N=49, Active, not recruiting, Fondazione Italiana Linfomi - ETS | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    CD19 (CD19 Molecule)
    |
    Rituxan (rituximab) • cytarabine • bendamustine • Zynlonta (loncastuximab tesirine-lpyl)
    18d
    High Soluble Tumor Necrosis Factor Receptor 2 in Serum Is Associated With Inferior Overall Survival Across Major Lymphoma Subtypes. (PubMed, Am J Hematol)
    In tissue from a case of marginal zone lymphoma, high TNFR2 expression was found on CD4+ and CD8+ T cells, B cells, and monocytes but also directly on tumor cells. We conclude sTNRF2 is a strong prognostic biomarker of OS across major lymphoma subtypes and may be useful to guide therapeutic choices, including targeted therapies against immunosuppressive TNFR2-expressing Tregs.
    Journal
    |
    CD8 (cluster of differentiation 8) • TNFA (Tumor Necrosis Factor-Alpha) • CD4 (CD4 Molecule)
    19d
    A Study of Glofitamab and Lenalidomide in People With Mantle Cell Lymphoma (clinicaltrials.gov)
    P1, N=39, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    CD20 (Membrane Spanning 4-Domains A1) • TNFA (Tumor Necrosis Factor-Alpha)
    |
    lenalidomide • Gazyva (obinutuzumab) • Columvi (glofitamab-gxbm)
    21d
    Targeting UHRF1 induces regression of aggressive mantle cell lymphoma. (PubMed, Leukemia)
    Our results reveal that the SOX11-UHRF1 regulatory axis is a critical modulator of tumor cell growth and proliferation and identify UHRF1 as a key oncogenic driver in MCL. Additionally, CM272's antitumor effect was validated in preclinical MCL animal models while exhibiting an acceptable safety profile.
    Journal
    |
    SOX11 (SRY-Box Transcription Factor 11) • UHRF1 (Ubiquitin Like With PHD And Ring Finger Domains 1)